SAN FRANCISCO, U.S. & SUZHOU, China | December 25, 2025 — Innovent Biologics announced that TABOSUN® (ipilimumab N01 injection), China’s first domestically developed anti-CTLA-4 monoclonal antibody, has received marketing approval from the National Medical Products Administration (NMPA). The approval covers combination neoadjuvant therapy with TYVYT® (sintilimab injection) for patients with stage IIB–III resectable MSI-H/dMMR colon cancer, marking a global first for a dual immune-oncology regimen in this clinical setting.
Science Significance
From a scientific perspective, the approval represents a major advance in immune-oncology strategy for early-stage colon cancer. TABOSUN®, a fully human CTLA-4 monoclonal antibody, works by releasing inhibitory immune checkpoints, thereby enhancing T-cell activation and antitumor immune responses. When combined with the PD-1 inhibitor TYVYT®, the dual-checkpoint blockade demonstrated remarkably high pathological complete response (pCR) rates, exceeding 80% in pivotal studies. These results highlight a synergistic immunologic mechanism that effectively targets tumors historically resistant to chemotherapy, particularly MSI-H/dMMR colon cancer, which accounts for roughly 15% of resectable cases. Scientifically, the findings validate short-course neoadjuvant immunotherapy as a disease-modifying approach rather than a purely palliative intervention.
Regulatory Significance
Regulatorily, the NMPA approval reflects successful navigation of one of the most rigorous biologics review pathways in Asia. Approval was supported by data from the randomized, controlled, multicenter Phase 3 NeoShot trial, which met its primary endpoints of pCR and event-free survival at interim analysis. The decision underscores regulatory confidence in Innovent’s clinical development, CMC controls, and pharmacovigilance readiness for a complex biologic combination. As the first domestic CTLA-4 antibody approved in China, TABOSUN® sets a new benchmark for local innovation under global cGxP standards, including GMP manufacturing, quality consistency, and post-marketing surveillance obligations.
Business Significance
Advertisement
From a business standpoint, the approval is a strategic milestone for Innovent, reinforcing its position as a leading biopharmaceutical innovator in China’s oncology market. The launch of TABOSUN® expands Innovent’s immune-oncology portfolio and strengthens the commercial lifecycle of TYVYT®, which already holds multiple reimbursed indications. Being the only dual-IO neoadjuvant regimen approved globally for colon cancer, the therapy offers strong differentiation in a competitive market. The approval also enhances Innovent’s manufacturing scale utilization, supply chain resilience, and long-term revenue potential while demonstrating the company’s ability to deliver first-in-class and best-in-class biologics.
Patients’ Significance
For patients, the impact is profound. MSI-H/dMMR colon cancer patients historically face limited benefit from chemotherapy, high recurrence risk, and significant treatment-related toxicity. The TABOSUN® plus TYVYT® regimen enables most patients to achieve complete pathological response prior to surgery, allowing many to avoid postoperative adjuvant chemotherapy altogether. This translates into reduced treatment burden, improved quality of life, and potentially better long-term survival outcomes. Importantly, preservation of surgical options with high R0 resection rates positions this therapy as a transformative standard of care in the neoadjuvant setting.
Policy Significance
At the policy level, the approval signals the maturation of China’s biologics regulatory ecosystem and its alignment with international innovation standards. Supporting domestically developed checkpoint inhibitors advances national goals around pharmaceutical self-reliance, affordability, and equitable patient access. The decision also reinforces policy momentum toward evidence-based neoadjuvant immunotherapy, encouraging regulators and payers to consider early-intervention strategies that reduce downstream healthcare costs, including chemotherapy-related toxicity and disease recurrence.
Overall, the NMPA approval of TABOSUN® in combination with TYVYT® marks a landmark achievement in biopharmaceutical innovation, regulatory execution, and patient-centric oncology care. As the world’s first approved dual-IO neoadjuvant therapy for colon cancer, the regimen not only redefines treatment paradigms for MSI-H/dMMR disease but also highlights how robust science, compliant development, and regulatory rigor can converge to deliver meaningful clinical breakthroughs. For the global cGxP community, the milestone underscores the growing role of China-originated biologics in shaping future standards of cancer care.
Source: Innovent Biologics press release
